Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.

Breast cancer research and treatment - 1 May 2018

Fostira Florentia, Saloustros Emmanouil, Apostolou Paraskevi, Vagena Andromahi, Kalfakakou Despoina, Mauri Davide, Tryfonopoulos Dimitrios, Georgoulias Vassileios, Yannoukakos Drakoulis, Fountzilas Georgios, Konstantopoulou Irene

Abstract excerpt

PURPOSE: Male breast cancer (MBC) is a rare cancer entity, with mutations in BRCA1 and BRCA2 genes accounting for ~ 10% of patients. Multiple-gene sequencing has already entered clinical practice for female breast cancer, whereas the performance of panel testing in MBC has not been studied extensively. Therefore, the aim of this study was to evaluate the clinical utility of panel testing for MBC, by the largest...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms, Male

Share to Checkpoint Kinase 2

Share to Founder Effect

Share to Germ-Line Mutation

Share to Loss of Function Mutation

Share to Sequence Deletion

Source

Identifiers

PMID: 29335925
DOI: 10.1007/s10549-018-4661-x

Genes

BRCA2
ATM
BRCA1
FANCL
PMS2
CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.PMID 29335925Read ↗

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.Semantic proximity Read ↗

Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.Semantic proximity Read ↗

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in ItalySemantic proximity Read ↗

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.Semantic proximity Read ↗

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.Semantic proximity Read ↗

Male Breast Cancer: From Molecular Genetics to Clinical ManagementSemantic proximity Read ↗

The molecular genetic make-up of male breast cancerSemantic proximity Read ↗

Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2.Semantic proximity Read ↗

Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.Semantic proximity Read ↗

Genetic Predisposition to Male Breast Cancer: A Case Series.Semantic proximity Read ↗

BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.Semantic proximity Read ↗

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.